Clovis Oncology Gestione
Gestione criteri di controllo 3/4
Clovis Oncology Il CEO è Patrick Mahaffy, nominato in Apr2009, ha un mandato di 14.25 anni. possiede direttamente 0.67% delle azioni della società, per un valore di $ 14.56K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7.4 anni e 14.3 anni.
Informazioni chiave
Patrick Mahaffy
Amministratore delegato
n/a
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | 14.3yrs |
| Proprietà del CEO | 0.7% |
| Durata media del management | 7.4yrs |
| Durata media del Consiglio di amministrazione | 14.3yrs |
Aggiornamenti recenti sulla gestione
Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17
Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$252m |
| Jun 30 2022 | n/a | n/a | -US$263m |
| Mar 31 2022 | n/a | n/a | -US$258m |
| Dec 31 2021 | US$3m | US$739k | -US$265m |
| Sep 30 2021 | n/a | n/a | -US$299m |
| Jun 30 2021 | n/a | n/a | -US$310m |
| Mar 31 2021 | n/a | n/a | -US$336m |
| Dec 31 2020 | US$3m | US$721k | -US$369m |
| Sep 30 2020 | n/a | n/a | -US$370m |
| Jun 30 2020 | n/a | n/a | -US$385m |
| Mar 31 2020 | n/a | n/a | -US$413m |
| Dec 31 2019 | US$7m | US$719k | -US$400m |
| Sep 30 2019 | n/a | n/a | -US$400m |
| Jun 30 2019 | n/a | n/a | -US$396m |
| Mar 31 2019 | n/a | n/a | -US$377m |
| Dec 31 2018 | US$6m | US$689k | -US$368m |
| Sep 30 2018 | n/a | n/a | -US$321m |
| Jun 30 2018 | n/a | n/a | -US$291m |
| Mar 31 2018 | n/a | n/a | -US$366m |
| Dec 31 2017 | US$9m | US$636k | -US$346m |
| Sep 30 2017 | n/a | n/a | -US$365m |
| Jun 30 2017 | n/a | n/a | -US$370m |
| Mar 31 2017 | n/a | n/a | -US$324m |
| Dec 31 2016 | US$789k | US$224k | -US$349m |
Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Patrick sia ragionevole rispetto ad aziende di dimensioni simili nel mercato US.
Compensazione vs guadagni: La retribuzione di Patrick è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Patrick Mahaffy (60 yo)
14.3yrs
Mandato
US$2,639,083
Compensazione
Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 14.3yrs | US$2.64m | 0.67% $ 14.6k | |
| Executive VP & CFO | 7.3yrs | US$1.19m | 0.072% $ 1.6k | |
| Executive VP | 7.5yrs | US$1.20m | 0.068% $ 1.5k | |
| Executive VP of Clinical Development & Pharmacovigilance and Chief Medical Officer | 7.9yrs | US$1.24m | 0.078% $ 1.7k | |
| Executive VP & Chief Scientific Officer | 3.8yrs | Nessun dato | Nessun dato | |
| Executive Vice President of Human Resources | 6.8yrs | Nessun dato | Nessun dato |
7.4yrs
Durata media
58yo
Età media
Gestione esperta: Il team dirigenziale di CLVS.Q è esperto e expertise (durata media dell'incarico 7.4 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 14.3yrs | US$2.64m | 0.67% $ 14.6k | |
| Independent Director | 14.3yrs | US$260.00k | 0.041% $ 889.9 | |
| Independent Director | 14.5yrs | US$270.00k | 0.040% $ 875.1 | |
| Independent Director | 14.5yrs | US$270.00k | 0.17% $ 3.8k | |
| Independent Director | 14.5yrs | US$270.00k | 0.044% $ 953.2 | |
| Independent Chairman | 10.5yrs | US$287.50k | 0% $ 0 | |
| Independent Director | 14.5yrs | US$257.50k | 0.040% $ 872.7 | |
| Director | 2yrs | US$375.21k | Nessun dato | |
| Independent Director | 10.5yrs | US$259.58k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$257.50k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$255.00k | 0% $ 0 |
14.3yrs
Durata media
67yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di CLVS.Q è composto da personale esperto e esperto (durata media dell'incarico 14.3 anni).